Good morning! We've finished the Agenda now
1pm: all done for today! Thank you.
Name (Mkt Cap) | RNS | Summary | Our view (Author) |
---|
Assura (LON:AGR) (£1.3bn) | Possible Offer | KKR says it made four proposals to buy AGR, latest at 48p. All were rejected by AGR board (SP: 39p). | AMBER/GREEN (Graham) Based on the current share price it still offers a nearly 10% return if it can get up to its Sep 2024 TNAV, plus a yield of nearly 9%. On track to deleverage according to a recent trading update. |
MONY (LON:MONY) (£1.0bn) | Final Results | 2024 rev +2% to £439m, adj EPS +5% to 17.1p. 2025 adj EBITDA to be “broadly within” consensus. | GREEN (Graham) Top-line growth is limited and the company has a big exposure to rising advertising costs. But almost everything else about MONY looks perfect to me, so I maintain my positive stance. Also please see my 12 Stocks of Christmas article. |
Oxford BioMedica (LON:OXB) (£414m) | Full Year TU | 2024 was in line. Organic revenue growth 78-81%. EBITDA profitability in H2. Outlook in line. | |
Frp Advisory (LON:FRP) (£344m) | TU & Dividend | FY April 2025 will be ahead of expectations. All service pillars ahead. Q3 divi 0.95p (LY: 0.9p). | GREEN (Roland - I hold) Broker forecasts have been upgraded for FY25 and FY26. Strong quality metrics and a modest valuation support my positive view, despite the risks inherent in fast-growing professional services businesses. |
Wilmington (LON:WIL) (£336m) | Half-year Report | Trading is in line. Net cash £31m. Organic revenue +3%, total revenue +16% (acquisitions). | AMBER/GREEN (Graham) This group of training businesses doesn't strike me as particularly cheap and there is some complexity to be digested, so I'm downgrading it from GREEN. |
hVIVO (LON:HVO) | £2m contract win | New client has signed contract for a hMPV trial following hVIVO/s successful recent hMPV pilot. | AMBER (Roland) [no section below] hVivo has a strong market position in human drug trials and strong quality metrics. Net cash provides some protection but earnings seem to be trending lower, perhaps due to poor visibility on client demand. A modest P/E of 12 may offer opportunity, but today’s contract win has not changed forecasts. I’m staying neutral. |
Springfield Properties (LON:SPR) (£117m) | Interim Results & Land Sale Agreement | £64m land sale to Barratt. H1 adj PBT up 90% to £3.8m. FY25 profit to be sig. ahead of exps. | |
Already have an account?
Login here
About the Author
I've been a full-time stock market analyst and investor since 2009, with the exception of one "year out"!I was a chartist (technical analyst) for three years, analysing the fixed income and futures markets for hedge funds and investment bank traders.After that I moved over to the buyside where I got my CFA qualification and learned how to manage equities and fixed income portfolios for a large institution. When given the chance to manage a diversified UK equity portfolio, I generated a return of 28.5% in two years (benchmark: 17.1%). Avoiding the mining sector was a big help!
I then took my year out to study Mandarin in China. Ever since, I've been spreading the word on how individuals can find exciting investment opportunities. I've spoken at countless events, taught financial statement analysis to private investors, built up a small following on social media, and have been a regular fixture here at Stockopedia for many years. The stock market continues to fascinate me and I'm sure it always will. more »
>